Cargando…

Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era

BACKGROUND: To evaluate the safety profile and efficacy of intravesical gemcitabine as first-line adjuvant therapy for non-muscle invasive bladder cancer (NMIBC) in the setting of ongoing Bacillus Calmette-Guérin (BCG) shortage. METHODS: We performed an institutional, retrospective review of patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Jiping, Funk, Joel, Lee, Benjamin R., Hsu, Chiu-Hsieh, Messing, Edward M., Chipollini, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323448/ https://www.ncbi.nlm.nih.gov/pubmed/37426602 http://dx.doi.org/10.21037/tau-22-772

Ejemplares similares

The BCG Shortage
por: Messing, Edward M.
Publicado: (2017)

Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation
por: Lin, Po-Ting, et al.
Publicado: (2022)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
por: Veeratterapillay, Rajan, et al.
Publicado: (2016)

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study
por: Gunelli, R, et al.
Publicado: (2007)

Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage
por: Nikas, Christine V., et al.
Publicado: (2020)

The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality
por: Harris, Rebecca C., et al.
Publicado: (2016)

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder
por: Mohanty, N. K., et al.
Publicado: (2008)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?
por: Elsawy, Amr A., et al.
Publicado: (2023)

BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)

Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
por: Hurle, Rodolfo, et al.
Publicado: (2020)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Healthcare policy changes in an era of health workforce shortage
por: Angel, Yoel, et al.
Publicado: (2023)

Economic impacts of the Bacillus Calmette-Guérin (BCG) therapy shortage and the proposed solutions for patients with non-muscle invasive bladder Cancer in Aseer Province, Saudi Arabia
por: Alshyarba, Mishari HM, et al.
Publicado: (2020)

Clinical registries in upper tract urothelial carcinoma: commitment to collaboration
por: Zeng, Jiping, et al.
Publicado: (2023)

Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model
por: Xiao, Zhengwen, et al.
Publicado: (2011)

Perioperative outcomes of open vs. robotic radical cystectomy: a nationwide comparative analysis (2008–2014)
por: Harb-De la Rosa, Alfredo, et al.
Publicado: (2020)

Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)

Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Kashif Khan, Muhammad, et al.
Publicado: (2014)

Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy
por: KRAJEWSKI, WOJCIECH, et al.
Publicado: (2020)

Complete response to intravesical gemcitabine in non‐muscle invasive bladder cancer patient after BCG failure: A case report and literature review
por: Nahhat, Fouad, et al.
Publicado: (2022)

Leiomyosarcoma of the scrotum: a case report and literature review
por: Zeng, Jiping, et al.
Publicado: (2021)

Pancreas Cancer Survival in the Gemcitabine Era
por: Wachtel, Mitchell S., et al.
Publicado: (2008)

Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Huang, Haichao, et al.
Publicado: (2014)

BCG Induced Necrosis of the Entire Bladder Urothelium
por: Krönig, Malte, et al.
Publicado: (2015)

Recognition and Treatment of BCG Failure in Bladder Cancer
por: Lightfoot, Andrew J., et al.
Publicado: (2011)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Erroneous treatment of syphilis with benzyl penicillin in an era with benzathine benzylpenicillin shortages
por: Nieuwenburg, Silvia, et al.
Publicado: (2020)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?
por: Lebacle, Cedric, et al.
Publicado: (2021)

Genomic analysis of response to bacillus Calmette-Guérin (BCG) treatment in high-grade stage 1 bladder cancer patients
por: Sanders, J. Alexa, et al.
Publicado: (2021)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial
por: Bhargava, Priyank
Publicado: (2023)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
por: Lim, Chun Jye, et al.
Publicado: (2021)

Committees and the Shortage of Resident Medical Officers : Is There Shortage?
Publicado: (1914)

Clinical evaluation of COVID-19/SARS-CoV-2 diagnostic testing in asymptomatic urology patients: implications for resumption of elective surgical care
por: Zeng, Jiping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0hpscmrd9nfvuj5aooi7n6ng4g